Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
NCT07546240

Optimal Radiotherapy - Heel Spur Syndrome - Randomized Clinical Trial

Led by Maria Sklodowska-Curie National Research Institute of Oncology · Updated on 2026-04-22

366

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Heel Spur Syndrome (HSS), is a pathology characterized by chronic inflammation and degenerative changes that affect approximately 10% of adults. Although many patients respond to conservative care, about 30% experience persistent pain. Low-dose radiation therapy (LDRT) is a well-established European method with proven anti-inflammatory and immunomodulatory effects. The ORHEELS trial aims to assess whether a Polish standard dose of 6 Gy in 6 daily fractions (fx)(5 times/week) is not inferior to the treatment with total dose of 3 Gy / fx 0,5 Gy /fractionated twice weekly. The study is designed to assess the impact of intensity of treatment (daily (5 times / week) versus twice weekly fractionation) on clinical outcomes.

CONDITIONS

Official Title

Optimal Radiotherapy - Heel Spur Syndrome - Randomized Clinical Trial

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 40 years or older
  • Clinically confirmed painful Heel Spur Syndrome (plantar fasciitis) persisting for at least 3 months
  • No effect from previous orthopaedic, physical, or analgesic treatments
  • General performance status ZUBROD 0-3
  • Exclusion of other local conditions
  • Patient readiness for follow-up contact
Not Eligible

You will not qualify if you...

  • Prior radiotherapy for heel spur
  • Local use of corticosteroids within 4 weeks before planned radiotherapy
  • Previous trauma or surgery to the foot on the same side
  • Systemic diseases such as collagen vascular disease
  • Pregnancy or breastfeeding
  • Lack of written informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch

Gliwice, Poland, 44-102

Actively Recruiting

Loading map...

Research Team

I

Iwona Dębosz-Suwińska

CONTACT

M

Mateusz Gajek

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here